Laparoscopic colorectal resection combined with simultaneous thermal ablation or surgical resection of liver metastasis: a retrospective comparative study

Figures & data

Figure 1. CONSORT 2010 flow diagram.

Table 1. Characteristics of patients in resection and ablation groups.

	Resection (n = 23)	Ablation (n = 45)	p Value
Number	23	45
Age	58 ± 12.12	61.62 ± 12.22	.251
Gender (male/female)	16/7	31/14	.954
BMI	21.60 ± 3.32	22.83 ± 3.26	.148
Smoking status	9	21	.554
ASA (1/2/3)	2/13/8	14/21/10	.108
Child–Pugh (A/B/C)	20/3/0	43/2/0	.327
Neoadjuvant chemotherapy	2	12	.085
Colon/rectum	14/9	16/29	.047
Albumin	39.47 ± 5.01	39.85 ± 3.98	.726
CEA	27.18 ± 36.95	12.15 ± 20.94	.08
Preoperative anemia	9	22	.445
T stage (1–3/4)	4/19	14/31	.214
N stage (N0/N+)	5/19	12/33	.592
CRLM number (1/2/3)	16/2/5	18/13/14	.042
CRLM maximal diameter (mm)	24.69 ± 11.87	22.69 ± 10.37	.475
CRLM location (unilobar/multilobar)	20/3	29/16	.041
Comorbidities
Diabetes mellitus	5	7	.572
Hypertension	5	6	.373
Cardiovascular disease	2	3	1
COPD	4	6	.724
Cerebrovascular	0	1	1

Note: The bold values represents as statistically significant p < .05.

Table 2. Perioperative outcomes for resection and ablation groups.

	Resection (n = 23)	Ablation (n = 45)	p Value
Surgical time (min)	286.70 ± 78.33	313.67 ± 80.90	.191
Transfusion	13	4	.0001
Conversion	2	0	.111
Margin status (R0)	23	NA
Postoperative LOS (d)	12.82 ± 9.25	8.40 ± 2.38	.034
Expenses (kRMB)	81.51 ± 20.20	82.21 ± 27.81	.914
Postoperative complications	11	24	.667
Anastomotic fistula	1	2	1
Hemorrhage	2	3	1
Pancreatitis	0	1	1
Hepatic abscess	0	2	.546
SSIs	3	8	.738
Ileus	1	0	1
Urinary infection	1	0	1
Diarrhea	0	1	1
Pulmonary infection	3	6	1
Readmission	0	1	1

Note: The bold values represents as statistically significant p < .05.

Figure 2. Overall survival, disease-free survival and intra-hepatic recurrent-free survival between ablation and resection groups.

Table 3. Characteristics of patients with solitary CRLM in resection and ablation subgroups.

	Resection (n = 16)	Ablation (n = 18)	p Value
Number	16	18
Age	60.37 ± 11.75	64.56 ± 9.57	.262
Gender (male/female)	10/6	11/7	.934
BMI	21.30 ± 3.31	22.33 ± 3.05	.353
Smoking status	7	8	.968
ASA (1/2/3)	0/8/8	5/9/4
Child–Pugh (A/B/C)	13/3/0	17/1
Neoadjuvant chemotherapy	1	5	.180
Colon/rectum	10/6	13/5	.545
Albumin	38.63 ± 5.47	39.24 ± 3.89	.712
CEA	23.42 ± 33.74	16.62 ± 29.61	.536
Preoperative anemia	6	9	.464
T stage (1–3/4)	3/13	4/14	.803
N stage (N0/N+)	2/14	4/14	.660
CRLM maximal diameter (mm)	24.38 ± 12.12	25.06 ± 11.65	.869
Comorbidities
Diabetes mellitus	5	3	.429
Hypertension	5	5	.824
Cardiovascular disease	1	1	1
COPD	1	0	.471
Cerebrovascular	0	1	1

Table 4. Perioperative outcomes for patients with solitary CRLM in resection and ablation subgroups.

	Resection (n = 16)	Ablation (n = 18)	p Value
Surgical time (min)	273.93 ± 79.95	288.61 ± 90.86	.623
Transfusion	8	2	.023
Conversion	1	0	.471
Postoperative LOS (d)	10.93 ± 4.26	7.39 ± 1.09	.005
Expenses (kRMB)	77.72 ± 15.25	81.73 ± 32.17	.653
Postoperative complications	6	11	.169
Anastomotic fistula	0	1	1
Hemorrhage	1	2	1
Pancreatitis	0	1	1
Hepatic abscess	0	1	1
SSIs	1	4	.340
Ileus	1	0	.471
Urinary infection	1	0	.471
Diarrhea	0	1	1
Pulmonary infection	2	0	.214
Readmission	0	1	1

Note: The bold values represents as statistically significant p < .05.

Figure 3. Overall survival, disease-free survival and intra-hepatic recurrent-free survival of solitary CRLM between ablation and resection groups.